{"filing":{"accession_number":"0001600620-26-000059","cik":"0001600620","ticker":"AUPH","company_name":"Aurinia Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"auph-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/auph-20260806.htm"},"events":[{"id":25824,"run_id":23443,"accession_number":"0001600620-26-000059","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Aurinia's financial results for the three and six months ended June 30, 2026. The Item 2.02 filing explicitly states \"Aurinia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement, cash flows) and key metrics including total revenue of $160.9 million (up 21% YoY), net income of $71.8 million (up 60% YoY), and diluted EPS of $0.53 (up 66% YoY), along with updated 2026 guidance.","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26749,"accession_number":"0001600620-26-000059","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Aurinia's financial results for the three and six months ended June 30, 2026. The Item 2.02 filing explicitly states \"Aurinia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement, cash flows) and key metrics including total revenue of $160.9 million (up 21% YoY), net income of $71.8 million (up 60% YoY), and diluted EPS of $0.53 (up 66% YoY), along with updated 2026 guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:36:27.282536+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26749,"accession_number":"0001600620-26-000059","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Aurinia's financial results for the three and six months ended June 30, 2026. The Item 2.02 filing explicitly states \"Aurinia Pharmaceuticals Inc. issued a press release announcing its financial results for the three months ended June 30, 2026,\" with the press release attached as Exhibit 99.1. The exhibit contains detailed financial statements (balance sheet, income statement, cash flows) and key metrics including total revenue of $160.9 million (up 21% YoY), net income of $71.8 million (up 60% YoY), and diluted EPS of $0.53 (up 66% YoY), along with updated 2026 guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:36:27.282536+00:00","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-08-06"}]}